Home
About Opexa
About Opexa
Management Team
Board of Directors
Scientific Advisory Board
Facility
Contact Us
Tcelna®
Tcelna® Description
TERMS Phase 2b Overview
MS Overview
Publications
OPX-212
OPX-212 Description
Neuromyelitis Optica
Clinical Trials
Abili-T Clinical Study for Secondary Progressive Multiple Sclerosis Overview
ImmForm® Clinical Management Tool
Technology
T-cell Platform
Opexa cGMP Manufacturing
Pipeline
News & Resources
Multimedia
Press Releases
Webcasts
Publications
Conference & Meeting Presentations
Investor Relations
Why Invest
Press Releases
Events & Presentations
Stock Information
SEC Filings
Financial Reports
Corporate Governance
Analyst Coverage
Investor FAQs
Careers
Working at Opexa
Open Positions
How to Apply
Living in The Woodlands
Contact Us
Contact Us
Precision Immunotherapy™
Home
/
Investor Relations
/
SEC Filings
/
SEC Filings Details
Investor Relations
Why Invest
Press Releases
Events & Presentations
Stock Information
SEC Filings
Financial Reports
Corporate Governance
Analyst Coverage
Investor FAQs
Why Invest
Press Releases
Events & Presentations
Stock Information
SEC Filings
Financial Reports
Corporate Governance
Analyst Coverage
Investor FAQs
Quick Links
Financial Reports
FAQs
Contact IR
About Opexa
Tcelna®
Clinical Trials
Contact Us
Email Alerts
Email Address
*
Mailing Lists
*
Releases
SEC Filings
Presentation
Events
Enter the code shown above.
*
Unsubscribe from email alerts
DEF 14A
04/11/2021
Proxy Statement (definitive)
© 2017 Opexa Therapeutics, Inc. All Rights Reserved.
Privacy Policy
Terms of Use
Powered By Q4 Inc.
4.4.0.14